Starpharma Holdings Limited (SPHRF)

Market Cap	33.30M
Revenue (ttm)	3.84M
Net Income (ttm)	-6.55M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,821
Average Volume	13,126
Open	0.0982
Previous Close	0.0840
Day's Range	0.0982 - 0.0982
52-Week Range	0.0540 - 0.0982
Beta	0.32
RSI	54.06
Earnings Date	Aug 22, 2025

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of a dendrimer-enhanced product (DEP...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 40
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPHRF

Financial Performance

In 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.

Financial numbers in AUD